Serotonin syndrome.

Jacqueline Volpi-Abadie, Adam M Kaye, Alan David Kaye
Author Information
  1. Jacqueline Volpi-Abadie: Department of Anesthesiology, Ochsner Clinic Foundation, New Orleans, LA.
  2. Adam M Kaye: Departments of Anesthesiology and Pharmacology, Louisiana State University School of Medicine, New Orleans, LA.
  3. Alan David Kaye: Departments of Anesthesiology and Pharmacology, Louisiana State University School of Medicine, New Orleans, LA.

Abstract

BACKGROUND: Serotonin syndrome is a potentially life-threatening syndrome that is precipitated by the use of serotonergic drugs and overactivation of both the peripheral and central postsynaptic 5HT-1A and, most notably, 5HT-2A receptors. This syndrome consists of a combination of mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity. Serotonin syndrome can occur via the therapeutic use of serotonergic drugs alone, an intentional overdose of serotonergic drugs, or classically, as a result of a complex drug interaction between two serotonergic drugs that work by different mechanisms. A multitude of drug combinations can result in serotonin syndrome.
METHODS: This review describes the presentation and management of serotonin syndrome and discusses the drugs and interactions that can precipitate this syndrome with the goal of making physicians more alert and aware of this potentially fatal yet preventable syndrome.
CONCLUSION: Many commonly used medications have proven to be the culprits of serotonin syndrome. Proper education and awareness about serotonin syndrome will improve the accuracy of diagnosis and promote the institution of the appropriate treatment that may prevent significant morbidity and mortality.

Keywords

References

  1. N Engl J Med. 2005 Mar 17;352(11):1112-20 [PMID: 15784664]
  2. Ann Pharmacother. 1997 Feb;31(2):175-7 [PMID: 9034418]
  3. Neurochem Int. 2003 Jul;43(2):155-64 [PMID: 12620284]
  4. J Psychopharmacol. 2010 Oct;24(10):1433-8 [PMID: 19423610]
  5. Drug Saf. 1997 Dec;17(6):390-406 [PMID: 9429838]
  6. Psychiatry Clin Neurosci. 2002 Oct;56(5):533-5 [PMID: 12193243]
  7. Neuropharmacology. 2007 Oct;53(5):643-56 [PMID: 17765930]
  8. Am Fam Physician. 2010 May 1;81(9):1139-42 [PMID: 20433130]
  9. Int J Emerg Med. 2010 Aug 20;3(4):373-7 [PMID: 21373307]
  10. J Emerg Med. 1998 Jul-Aug;16(4):615-9 [PMID: 9696181]
  11. Gen Hosp Psychiatry. 2008 Jul-Aug;30(4):372-7 [PMID: 18585543]
  12. J Toxicol Clin Toxicol. 2004;42(3):277-85 [PMID: 15362595]
  13. Ann Pharmacother. 2004 Mar;38(3):411-3 [PMID: 14970364]
  14. QJM. 2003 Sep;96(9):635-42 [PMID: 12925718]
  15. Brain Res. 2001 Jan 26;890(1):23-31 [PMID: 11164765]
  16. Ann Pharmacother. 2001 Jul-Aug;35(7-8):870-3 [PMID: 11485136]
  17. Aust N Z J Psychiatry. 2007 Aug;41(8):649-55 [PMID: 17620161]
  18. J Clin Psychopharmacol. 2002 Aug;22(4):440-1 [PMID: 12172351]
  19. Psychosomatics. 2009 Nov-Dec;50(6):638-9 [PMID: 19996237]
  20. Gen Hosp Psychiatry. 2008 May-Jun;30(3):284-7 [PMID: 18433663]
  21. J Indian Med Assoc. 2011 Jan;109(1):36-7 [PMID: 21888157]
  22. J Clin Psychopharmacol. 2000 Feb;20(1):103-5 [PMID: 10653219]
  23. Psychopharmacology (Berl). 2000 May;150(1):9-14 [PMID: 10867971]

Word Cloud

Created with Highcharts 10.0.0syndromedrugsserotoninserotonergicSerotonincanpotentiallyusehyperactivityresultdrugBACKGROUND:life-threateningprecipitatedoveractivationperipheralcentralpostsynaptic5HT-1Anotably5HT-2AreceptorsconsistscombinationmentalstatuschangesneuromuscularautonomicoccurviatherapeuticaloneintentionaloverdoseclassicallycomplexinteractiontwoworkdifferentmechanismsmultitudecombinationsMETHODS:reviewdescribespresentationmanagementdiscussesinteractionsprecipitategoalmakingphysiciansalertawarefatalyetpreventableCONCLUSION:ManycommonlyusedmedicationsprovenculpritsPropereducationawarenesswillimproveaccuracydiagnosispromoteinstitutionappropriatetreatmentmaypreventsignificantmorbiditymortalityDrugtoxicity

Similar Articles

Cited By